BD to close Israeli manufacturing plant and lay off 200 employees
BD to close Israeli manufacturing plant and lay off 200 employees
The global medical device company moving operations abroad as part of a strategy to streamline its supply chain.
The global medical device company BD (Becton Dickinson and Co) is closing its manufacturing operations in Israel and laying off 200 employees in Caesarea, Calcalist has learned. BD's operations in Israel stem from its 2017 acquisition of Caesarea Medical Electronics, which specialized in the production of infusion pumps for the domestic market. The company manufactures a wide range of medical devices used in hospitals, clinics, and pharmacies, including products for collecting biological samples, injecting drugs, and treating patients, among other applications. Before closing its operations, BD had numerous collaborations with local startups.
BD is traded on the New York Stock Exchange with a market value of $70 billion and employs 74,000 people globally.
The company stated: "BD is continuously reviewing its global manufacturing network and supply chain, with the aim of streamlining operations and better serving our customers around the world. After careful consideration, we have concluded that we can more effectively meet our customers’ needs and manufacturing capacity by utilizing other facilities, and have made the decision to move all manufacturing from Caesarea Medical Electronics Ltd. (CME) in Israel to other BD facilities around the world.
"We fully understand the impact this move may have on our dedicated employees. This decision does not reflect the exceptional work our employees do in Israel. BD is committed to supporting all employees affected by this move, which will continue until June 2025. We will actively seek potential opportunities for them within BD’s other operations or through job placement assistance. Our goal is to ensure that every individual is treated with respect and receives the support they need. As a responsible business, we must ensure that all of our operations are efficient and that our resources are allocated in the most effective manner possible. BD remains committed to serving its customers and contributing to the delivery of healthcare in Israel, and our commercial operations will not be impacted by this decision."
